Abstract
This study aimed to verify the effects of berberine (BBR) on the fat metabolism proteins involved in the sirtuin 3 (SIRT3)/adenosine 5’-monophosphate (AMP)-activated protein kinase (AMPK)/acetyl-CoA carboxylase (ACC) pathway in the liver tissues of rats with high-fat diet (HFD)-induced non-alcoholic fatty liver disease (NAFLD). Forty-eight rats were randomly divided into the normal control (NC) group, HFD group or BBR group, with 16 rats in each group. After 8 and 16 weeks of treatment, serum and liver samples were collected. Subsequently, body parameters, biochemical parameters and liver pathology were examined. The expression levels of proteins involved in the SIRT3/AMPK/ACC pathway in the liver were detected by Western blotting. After 8 and 16 weeks of a HFD, the successful establishment of rat models with different degrees of NAFLD was confirmed by hematoxylin and eosin (H&E) and Oil Red O staining. NAFLD rat models exhibited obesity and hyperlipidemia, and the protein expression levels of SIRT3, p-AMPK, p-ACC, and CPT-1A in the liver were significantly decreased compared to those in the NC group. The concurrent administration of BBR with the HFD effectively improved serum and liver lipid profiles and ameliorated liver injury. Furthermore, the protein expression levels of SIRT3, p-AMPK, p-ACC, and CPT-1A in the liver were significantly increased in the BBR group as compared with those in the HFD group. In conclusion, our data suggest that the mechanism by which BBR ameliorates HFD-induced hepatic steatosis may be related to the activation of the SIRT3/AMPK/ACC pathway in the liver.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Rinella ME. Nonalcoholic Fatty Liver Disease. JAMA, 2015,313(22):2263
Argo CK, Caldwell SH. Epidemiology and natural history of non–alcoholic steatohepatitis. Clin Liver Dis, 2009,13(4):511–531
Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol, 2013,10(11):686–690
Fan JG, Farrell GC. Epidemiology of non–alcoholic fatty liver disease in China. J Hepatol, 2009,50(1):204–210
Alisi A, Manco M, Panera N, et al. Association between type two diabetes and non–alcoholic fatty liver disease in youth. Ann Hepatol, 2009,8(Suppl 1):S44–S50
Nassir F, Ibdah JA. Role of mitochondria in nonalcoholic fatty liver disease. Int J Mol Sci, 2014,15(5):8713–8742
Osborne B, Bentley NL, Montgomery MK, et al. The role of mitochondrial sirtuins in health and disease. Free Radical Bio Med, 2016,100:164–174
Hirschey MD, Shimazu T, Goetzman E, et al. SIRT3 regulates mitochondrial fatty–acid oxidation by reversible enzyme deacetylation. Nature, 2010,464(7285):121–125
Hirschey MD, Shimazu T, Huang JY, et al. SIRT3 regulates mitochondrial protein acetylation and intermediary metabolism. Cold Spring Harb Symp Quant Biol, 2011,76:267–277
Shi T, Fan GQ, Xiao SD. SIRT3 reduces lipid accumulation via AMPK activation in human hepatic cells. J Dig Dis, 2010,11(1):55–62
Zhang SJ, Li YF, Wang GE, et al. Caffeine ameliorates high energy diet–induced hepatic steatosis: sirtuin 3 acts as a bridge in the lipid metabolism pathway. Food Funct, 2015,6(8):2578–2587
Ge Y, Zhang Y, Li R, et al. Berberine regulated Gck, G6pc, Pck1 and Srebp–1c expression and activated AMPactivated protein kinase in primary rat hepatocytes. Int J Biol Sci, 2011,7(5):673–684
Lee YS, Kim WS, Kim KH, et al. Berberine, a natural plant product, activates AMP–activated protein kinase with beneficial metabolic effects in diabetic and insulinresistant states. Diabetes, 2006,55(8):2256–2264
Yin J, Gao Z, Liu D, et al. Berberine improves glucose metabolism through induction of glycolysis. Am J Physiol Endocrinol Metab, 2008,294(1):E148–E156
Chang X, Yan H, Fei J, et al. Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high–fat diet in rats. J Lipid Res, 2010,51(9):2504–2515
Yan HM, Xia MF, Wang Y, et al. Efficacy of Berberine in Patients with Non–Alcoholic Fatty Liver Disease. PLos One, 2015,10(8):e134172
Teodoro JS, Duarte FV, Gomes AP, et al. Berberine reverts hepatic mitochondrial dysfunction in high–fat fed rats: a possible role for SirT3 activation. Mitochondrion, 2013,13(6):637–646
Gomes AP, Duarte FV, Nunes P, et al. Berberine protects against high fat diet–induced dysfunction in muscle mitochondria by inducing SIRT1–dependent mitochondrial biogenesis. Biochim Biophys Acta, 2012,1822(2):185–195
Zhao L, Cang Z, Sun H, et al. Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease. Bmc Endocr Disord, 2017,17:13
Guo T, Woo SL, Guo X, et al. Berberine Ameliorates Hepatic Steatosis and Suppresses Liver and Adipose Tissue Inflammation in Mice with Diet–induced Obesity. Sci Rep, 2016,6:22 612
Kim WS, Lee YS, Cha SH, et al. Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. Am J Physiol Endocrinol Metab, 2009,296(4):E812–E819
Sanches SC, Ramalho LN, Augusto MJ, et al. Nonalcoholic Steatohepatitis: A Search for Factual Animal Models. Biomed Res Int, 2015,2015:574832
Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology, 2010,51(2):679–689
Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science, 2011,332(6037):1519–1523
Vilar–Gomez E, Martinez–Perez Y, Calzadilla–Bertot L, et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology, 2015,149(2):367–378, e14–e15
Xie W, Gu D, Li J, et al. Effects and action mechanisms of berberine and Rhizoma coptidis on gut microbes and obesity in high–fat diet–fed C57BL/6J mice. PLos One, 2011,6(9):e24520
Chatrath H, Vuppalanchi R, Chalasani N. Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis, 2012,32(1):22–29
Hirschey MD, Shimazu T, Jing E, et al. SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome. Mol Cell, 2011,44(2):177–190
Wu T, Liu YH, Fu YC, et al. Direct evidence of sirtuin downregulation in the liver of non–alcoholic fatty liver disease patients. Ann Clin Lab Sci, 2014,44(4):410–418
Huang YY, Gusdon AM, Qu S. Nonalcoholic fatty liver disease: molecular pathways and therapeutic strategies. Lipids Health Dis, 2013,12:171
Kahn BB, Alquier T, Carling D, et al. AMP–activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab, 2005,1(1):15–25
Teodoro JS, Duarte FV, Gomes AP, et al. Berberine reverts hepatic mitochondrial dysfunction in high–fat fed rats: a possible role for SirT3 activation. Mitochondrion, 2013,13(6):637–646
Shukla S, Sharma A, Pandey VK, et al. Concurrent acetylation of FoxO1/3a and p53 due to sirtuins inhibition elicit Bim/PUMA mediated mitochondrial dysfunction and apoptosis in berberine–treated HepG2 cells. Toxicol Appl Pharmacol, 2016,291:70–83
Xu M, Xiao Y, Yin J, et al. Berberine promotes glucose consumption independently of AMP–activated protein kinase activation. PLos One, 2014,9(7):e103702
Author information
Authors and Affiliations
Corresponding author
Additional information
This work was supported by grants from the National Natural Science Foundation of China (No. 81573844 and No. 81774165) and Medical Research Fund of Guangdong Province (No. A2017363).
Rights and permissions
About this article
Cite this article
Zhang, Yp., Deng, Yj., Tang, Kr. et al. Berberine Ameliorates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Rats via Activation of SIRT3/AMPK/ACC Pathway. CURR MED SCI 39, 37–43 (2019). https://doi.org/10.1007/s11596-019-1997-3
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11596-019-1997-3